Review in Biochemical Society transactions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors.
Mariah Weber-StoutDepartment of Nutrition and Integrative Physiology and the Diabetes and Metabolism Research Center, University of Utah, Salt Lake City, UT 84112, U.S.A.ORCID 0009-0004-9747-2860
Rebekah J NicholsonDepartment of Nutrition and Integrative Physiology and the Diabetes and Metabolism Research Center, University of Utah, Salt Lake City, UT 84112, U.S.A.
Carlos Dave C DumaguitDepartment of Nutrition and Integrative Physiology and the Diabetes and Metabolism Research Center, University of Utah, Salt Lake City, UT 84112, U.S.A.
William L HollandDepartment of Nutrition and Integrative Physiology and the Diabetes and Metabolism Research Center, University of Utah, Salt Lake City, UT 84112, U.S.A.
Scott A SummersDepartment of Nutrition and Integrative Physiology and the Diabetes and Metabolism Research Center, University of Utah, Salt Lake City, UT 84112, U.S.A.ORCID 0000-0002-4919-0592
Funding
Interdisciplinary Training Program in MetabolismT32DK091317 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI SCOTT A SUMMERS · 2011 to 2026
$4.8M
Ceramides as novel drivers of metabolic dysfunction and colorectal cancerU01CA272529 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Mary Christine Playdon, SCOTT A SUMMERS · 2022 to 2026
$4.7M
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic DiseasesR44DK116450 · NIDDK · POTRERO HILL THERAPEUTICS, INC. · PI BLITZER, JEREMY, SUMMERS, SCOTT A · 2018 to 2022
$4.7M
Liver-islet and intra-islet cross talk in alpha cell hyperplasia and beta cell regenerationR01DK112826 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HOLLAND, WILLIAM L · 2017 to 2025
$3.4M
The Role of Ceramides in the Intestinal Stem CellR01DK131609 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI EDGAR, BRUCE ALEXANDER, SUMMERS, SCOTT A · 2021 to 2025
$2.5M
The Role of Ceramides in the Pancreatic Beta CellR01DK130296 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI HOLLAND, WILLIAM L, SUMMERS, SCOTT A · 2022 to 2025
$2.2M
Ceramides in Diastolic Heart FailureR01HL170575 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI WILLIAM L HOLLAND, SCOTT A SUMMERS · 2024 to 2026
$2.1M
Targeting a Ceramide Double Bond to Treat Cardiometabolic DisordersR01DK122001 · NIDDK · UNIVERSITY OF UTAH · PI SUMMERS, SCOTT A · 2019 to 2022
$1.9M
Targeting Ceramide Signaling: Enhancing Healthy Aging and Combating Tauopathy in MammalsR01AG085793 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SCOTT A SUMMERS, Liou Y. Sun · 2025 to 2026
$1.5M
Native American Research Internship (NARI) Summer Program in Diabetes, Obesity and MetabolismR25DK109894 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI HOLSTI, MAIJA, SUMMERS, SCOTT A · 2016 to 2025
$1.1M
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic DiseasesR43DK116450 · NIDDK · POTRERO HILL THERAPEUTICS, INC. · PI BLITZER, JEREMY, SUMMERS, SCOTT A · 2017 to 2017
$225k
Ceramides as Novel Mediators of Tubular Metabolic Dysfunction Driving Kidney InjuryF31DK134088 · NIDDK · UNIVERSITY OF UTAH · PI NICHOLSON, REBEKAH JOY · 2023 to 2024
Like 'influencers' who achieve fame and power through social media, ceramides are low abundance members of communication platforms that have a mighty impact on their surroundings. Ceramide microdomains form within sphingolipid-laden lipid rafts that confer detergent resistance to cell membranes and serve as important signaling hubs. In cells exposed to excessive amounts of saturated fatty acids (e.g. in obesity), the abundance of ceramide-rich microdomains within these rafts increases, leading to concomitant alterations in cellular metabolism and survival that contribute to cardiometabolic disease. In this mini-review, we discuss the evidence supporting the formation of these ceramide microdomains and describe the spectrum of harmful ceramide-driven metabolic actions under the context of an evolutionary theory. Moreover, we discuss the proximal 'followers' of these ceramide media stars that account for the diverse intracellular actions that allow them to influence obesity-linked disease.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Ceramide microdomains: the major influencers of the sphingolipid media platform. · full record | OpenQuestion